Author: Kamahori, Yoshihiro ; Matsuoka, Kazuaki ; Saeki, Hiroshi ; Maehara, Yoshihiko ; Shimada, Mitsuo ; Kitao, Hiroyuki ; Tsukihara, Hiroshi ; Oki, Eiji ; Ochiiwa, Hiroaki ; Ando, Koji ; Kakeji, Yoshihiro ; Yoshizumi, Tomoharu ; Nakanishi, Ryota ; Harimoto, Norifumi ; Shirabe, Ken ; Makino, Kunio ; Kataoka, Yuki ; Miyadera, Kazutaka ; Fujimoto, Yoshiaki ; Baba, Hideo ; Sagara, Takeshi ; Tokunaga, Eriko ; Takechi, Teiji ; Nonaka, Kentaro ; Kawazoe, Tetsuro ; Iimori, Makoto ; Wakasa, Takeshi ; Ota, Mitsuhiko

Prof. Setsuro Fujii achieved significant results in the field of drug discovery research in Japan. He developed nine well-known drugs: FT, UFT, S-1 and FTD/TPI are anticancer drugs, while cetraxate hydrochloride, camostat mesilate, nafamostat mesilate, gabexate mesilate and pravastatin sodium are therapeutic drugs for various other diseases. He delivered hope to patients with various diseases across the world to improve their condition. Even now, drug discovery research based on Dr. Fujii's ideas is continuing.

01 Jun 2010·Expert Review of Gastroenterology & HepatologyQ3 · MEDICINE

Rebamipide: a gastrointestinal protective drug with pleiotropic activities

Q3 · MEDICINE

Article

Author: Yoshikawa, Toshikazu ; Naito, Yuji

Rebamipide, a gastroprotective drug, was developed in Japan and was proven to be superior to cetraxate, the former most prescribed drug of the same category, in 1989 in the treatment for gastric ulcers. The initially discovered basic mechanisms of action of rebamipide included its action as a prostaglandin inducer and oxygen free-radical scavenger. In the last 5 years, several basic and clinical studies have been performed for functional dyspepsia, chronic gastritis, NSAID-induced gastrointestinal injuries, gastric ulcer following eradication therapy for Helicobacter pylori, gastric ulcer after endoscopic surgery and ulcerative colitis. In addition, several molecules have been identified as therapeutic targets of rebamipide to explain its pleiotropic pharmacological actions. The aim of this article is to provide an update on the pharmacological and clinical profile of rebamipide and to explore further possibilities for additional indications.

01 Feb 2007·InflammopharmacologyQ3 · MEDICINE

Are gastroprotective drugs useful for gastric ulcer healing: Re-evaluation using current ICH E9 guidelines

Q3 · MEDICINE

Article

Author: N. Oshitani ; T. Tanigawa ; T. Watanabe ; T. Arakawa ; Y. Fujiwara ; K. Tominaga ; K. Higuchi ; M. Shiba

Most of the gastroprotective drugs which had been marketed in Japan were considered to have insufficient rationale for use as ulcer treatments. Such drugs may have a crucial role in maintaining mucosal integrity by the mechanisms other than inhibition of acid secretion. We re-evaluated the effect of gastroprotective drugs on gastric ulcer healing using current ICH E9 guidelines. We collected reports of pivotal trials on healing rate of gastric ulcer with 9 kinds of gastroprotective drugs submitted in New Drug Applications. In the comparative trial of cetraxate vs. placebo, the healing rate of gastric ulcer at 8-week endoscopy in the cetraxate was significantly higher than that in the placebo groups (88.6% and 62.2%, p = 0.0062). Non-inferiority to cetraxate was confirmed for 8 kinds of gastroprotective drugs. In conclusion, the superiority of cetraxate over placebo and non-inferiority to cetraxate for 7 drugs was established in the respect of effect on ulcer healing.

100 Deals associated with Cetraxate Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02266	Cetraxate Hydrochloride	A02B	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute gastritis	JP	Alfresa Pharma Corp.	13 Mar 1979
Chronic gastritis	JP	Alfresa Pharma Corp.	13 Mar 1979
Stomach Ulcer	JP	Alfresa Pharma Corp.	13 Mar 1979

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis